What Makes Prescribing Medical?

There is an understandable assumption at the centre of Australia’s medicinal cannabis industry: that once somethinghas passed through the hands of a doctor, it becomes a medicine. The product is prescribed, the pharmacy dispenses it, and the patient may reasonably conclude that what has occurred is medical care.

Sometimes it is. Sometimes the doctor has investigated the patient’s circumstances, considered what the treatment is intended to change, weighed risk against benefit and returned later to ask whether anything useful actually happened. At other times, the consultation functions as little more than a gateway. The patient wants a drug; the doctor confirms basic eligibility; a prescription follows. The process is "lawful", efficient and commercially successful. But it is not necessarily much of a medical process.

I describe the latter as commercial prescribing. The phrase is not intended to suggest that commerce has no place in medicine. Most private healthcare involves payment, and convenient services can have genuine value. Commercial prescribing is something more specific: a relationship in which the medical role becomes subordinate to facilitating access to a product.

The gateway model

The clues are usually familiar. Consultations are brief and standardised. Success is measured in appointments completed, prescriptions issued or customers retained. Clinical complexity is inconvenient because complexity takes time, introduces uncertainty and may lead the doctor to say no—or, more subtly, to say, “Not yet; first we need to understand what is happening.”

For a stable person seeking continuation of an established treatment, a short appointment may be entirely reasonable. The problem is not brevity itself. It is whether the depth of the consultation is determined by the patient’s needs or by a business model designed to process access efficiently.

Some patients understandably prefer the gateway model. It is quick, minimally intrusive and may replace an illicit supply with a regulated one. Yet these benefits can conceal a poor bargain. A patient may receive exactly what was requested while losing the opportunity to discover what treatment could have achieved.

The duty does not disappear

A cannabis consultation remains a medical consultation. The person on the screen may have known illness, unrecognised disease, interacting medicines, dependency, worsening pain or an emerging psychiatric problem. The doctor’s responsibility does not disappear because the patient came asking for a particular substance, nor because the consultation occurred by telehealth.

This matters because regular substance use usually serves a purpose. Cannabis may be used for pain, sleep, apprehension, emotional regulation, loneliness or temporary distance from circumstances that feel intolerable. Increasing use may reflect tolerance or dependence, but it may also signal worsening illness, deteriorating mental health or a life beginning to come apart. Sometimes cannabis contributes to the deterioration; sometimes it is an attempted response to it; often the relationship is circular.

Patterns of prescribing and dispensing can make that trajectory visible. Earlier requests, increasing quantities, stronger products, frequent substitutions or an expanding collection of formulations are not diagnoses. They are reasons to become curious. A sequence that looks unremarkable when viewed as isolated transactions may look alarming when viewed as a clinical story.

For some people, the cannabis prescriber is their only continuing contact with healthcare. This is especially important among patients who feel injured by institutions and regard conventional clinicians as representatives of a society they no longer trust. A doctor cannot compel such a patient to accept wider care. But the possibility of intervention becomes vanishingly small if nobody notices that their circumstances have changed.

What the patient thinks a prescription provides

Patients may also overestimate the protection conferred by the word “prescribed”. A prescription is important: it demonstrates authorised therapeutic supply and may distinguish lawful possession from illicit possession. But it is not a universal shield against questions about driving, impairment, workplace safety, unsafe behaviour or use inconsistent with medical advice. In Australia, THC and driving remain a particularly consequential example: a prescription does not simply make the legal problem disappear.

Nor can a superficial prescriber necessarily provide the clinical account a patient expects when treatment is questioned. Why was cannabis chosen? What outcome was intended? How were adverse effects assessed? Was function improving? Were escalating quantities recognised? A prescription may be genuine while the surrounding evidence of responsible medical supervision is remarkably thin.

The patient may have done everything they thought was required. They saw a doctor, paid a fee and used a pharmacy. Yet if the system treated legality as a marketing promise rather than a disciplined clinical process, it may be the patient who discovers the limits of that promise.

Cannabis is not one effect

The less dramatic cost of commercial prescribing is poorer treatment. Cannabis is often discussed as though it were a single medicine arranged along a scale of THC strength. THC is its best-known intoxicating constituent, but a percentage printed on a label does not adequately predict the range of experiences patients report.

CBD, minor cannabinoids, formulation, route, dose, timing, tolerance and concurrent medicines may all matter. Mood, expectation and the circumstances in which cannabis is used matter as well. Claims about terpenes and an “entourage effect” frequently run ahead of reliable evidence, and intellectual honesty requires us to say so. But uncertainty is not evidence of simplicity. The familiar THC–CBD description is useful; it is not a complete clinical map.

When that complexity is ignored, prescribing easily degenerates into product accumulation and potency escalation. The patient changes varieties without learning which property produced benefit or harm. More THC is mistaken for more treatment. Intoxication, expense and tolerance rise while function remains unchanged.

Three things people are seeking

In practice, the effects people seek from cannabis fall broadly into three overlapping domains.

The first is relief from apprehension: fear, anxiety, rumination or the bodily arousal that accompanies them. Cannabis-related compounds can have markedly different effects here. Some people feel calmer; others become more vigilant, confused or frightened, particularly with higher exposure to THC.

The second is relief from physical tension or pain. This may include nociceptive pain, muscular tightness, rigidity or the subjective sense that the body has become less oppressive. Pain is a difficult beast to pin down. It is not one thing, and even when it arises from the same pathology it is not experienced identically from one day to the next. The medically useful question is therefore not merely whether pain scores fall, but whether the person can move, sleep, work, care for others or re-enter parts of life that pain had displaced.

The third is altered consciousness: anything from gentle euphoria and a little psychological distance to profound intoxication, perceptual disturbance and physical incapacity. Some people seek this deliberately. Others regard it as an unwanted price paid for relief. Many patients want the first two effects while remaining entirely grounded and functional.

Medicine is a direction, not a moral category

This complicates the familiar attempt to divide medical from recreational use. Pleasure does not invalidate treatment. Medicine does not require a therapy to be unpleasant before it can be legitimate, and occasional enjoyment of an effect does not transform a patient into a recreational user. Conversely, possession of a prescription does not make every pattern of use therapeutic.

The distinction is better found in purpose, proportionality and direction. What problem is being treated? What effect is being pursued? Is the patient functioning better? Is the benefit proportionate to impairment and risk? Is cannabis helping the person participate in life, or making withdrawal from life easier? Does the treatment remain responsive to evidence, or has prescribing become an automatic renewal of permission?

There is a wider and more difficult discussion here about escapism. Some people use intoxication because reality has become painful, and some are profoundly resistant to any suggestion that their use should be examined. They may experience clinical boundaries as moral condemnation or authoritarian control. That subject deserves care in its own right. Moral judgment can obstruct honest treatment; abandoning judgment altogether can become another form of neglect.

The authority and the obligation

The argument about commercial prescribing is easiest to make to doctors, pharmacists and regulators because they understand the professional penalties attached to poor practice. The public cost is more diffuse. It lies in missed illness, unmanaged deterioration, false reassurance, inferior treatment and a gradual erosion of what people think a doctor is there to do.

Society gives doctors unusual authority to prescribe substances that are otherwise restricted. That authority is not merely a convenient mechanism for distributing access. It rests on an expectation that the doctor will exercise independent judgment, consider the patient’s welfare, recognise foreseeable danger and respond when treatment is no longer serving its purpose.

Commercial healthcare is not inherently improper. The problem begins when commercial logic defines the limits of care—when medical authority is retained but the obligations that justify it are treated as optional. Medical cannabis prescribing, at its essence, is the purposeful pursuit of effects and outcomes. It asks what is changing, why it is changing and whether the person’s life is becoming more workable. Commercial prescribing asks a narrower question: can cannabis be supplied?

A prescription answers the second question. Medicine begins with the first.